Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia

Nephrology Dialysis Transplantation

Volumn 18, Issue 4, 2003, Pages 703-709

  Wilson, Stephanie H ^a   Chade, Alejandro R ^a   Feldstein, Ariel ^a   Sawamura, Tatsuya ^b   Napoli, Claudio ^c,d   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HMG CoA reductase inhibitors; Hyper cholesterolaemia; Kidney

Indexed keywords

3 NITROTYROSINE; ANTILIPEMIC AGENT; CHROMIUM DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NITRIC OXIDE SYNTHASE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIUM CELL; ENZYME INDUCTION; FROZEN SECTION; GLOMERULUS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY PERFUSION; KIDNEY TUBULE; LIPID OXIDATION; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK FACTOR; STAINING; SUPPLEMENTATION; SWINE;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; FEMALE; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION TESTS; NITRIC OXIDE SYNTHASE; PROBABILITY; RANDOM ALLOCATION; RECEPTORS, LDL; RECEPTORS, OXIDIZED LDL; REFERENCE VALUES; RENAL CIRCULATION; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; SWINE; TYROSINE;

EID: 0037383845     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg143     Document Type: Article

References (27)

1. Vazquez-Perez S, Aragoncillo P, de Las Heras N et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant 2001; 16 [Suppl 1]: 40-44
2. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease a meta-analysis. Kidney Int 2001; 59: 260-269
3. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71: S2-S5
4. Bentley MD, Rodriguez-Porcel M, Lerman A et al. Enhanced renal cortical vascularization in experimental hypercholesterolemia. Kidney Int 2002; 61: 1056-1063
5. Chade AR, Rodriguez-Porcel M, Grande J et al. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 2002; 106: 1165-1171
6. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statins effects beyond lipid lowering. Eur Heart J 2002; in press
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 60: 7-22
8. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213
9. Wilson SH, Best PJM, Lerman LO et al. Simvastatin improves coronary endothelial function independent of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 122-128
10. Buemi M, Senatore M, Corica F et al. Statins and progressive renal disease. Med Res Rev 2002; 22: 76-84
11. Krier JD, Ritman EL, Bajzer Z, Romero JC, Lerman A, Lerman LO. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol 2001; 281: F630-F638
12. Lerman LO, Nath KA, Rodriguez-Porcel M et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001; 37: 541-546
13. Bonetti PO, Wilson SH, Rodriguez-Porcel M, Holmes DR Jr, Lerman A, Lerman LO. Simvastatin preserves myocardial perfusion and microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 2002; 40: 546-554
14. Wassmann S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457
15. O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993; 22: 83-89
16. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31: 225-231
17. Hafez KS, Inman SR, Stowe NT, Novick AC. Renal hemodynamic effects of lovastatin in a renal ablation model. Urology 1996; 48: 862-867
18. Park JK, Muller DN, Mervaala EM et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000; 58: 1420-1430
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
20. Wilson SH, Herrmann J, Lerman LO et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-418
21. Hasler-Rapacz J, Kempen HJ, Princen HM, Kudchodkar BJ, Lacko A, Rapacz J. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine. Arterioscler Thromb Biol 1996; 16: 137-143
22. Carey GB. The swine as a model for studying exercise-induced changes in lipid metabolism. Med Sci Sports Exerc 1997; 29: 1437-1443
23. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-87
24. Park YS, Guijarro C, Kim Y et al. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998; 31: 190-194
25. Cooke CL, Davidge ST. Peroxynitrite increases iNOS through NF-kappaB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 2002; 282: C395-C402
26. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001; 289: 857-861
27. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis. part I. oxidative stress and atherogenesis. Circulation 2002; 105: 393-396